Antigen presentation via major histocompatibility complex class II molecule (MHC class II antigen presentation)

Antigen presentation via major histocompatibility complex (MHC) class II molecules is an essential component of adaptive immunity. This biological process occurs primarily in professional antigen-presenting cells—such as dendritic cells, macrophages, and B lymphocytes—which internalize extracellular antigens through endocytosis or phagocytosis. The antigens are processed into peptides within endosomal compartments where they bind newly synthesized MHC class II heterodimers composed of α and β chains. The peptide-MHC complexes are then transported to the cell surface for recognition by CD4+ T helper lymphocytes. This interaction triggers downstream immune responses including antibody production and orchestration of cellular immunity against pathogens and abnormal self-antigens such as those found in autoimmune diseases or cancer. Dysregulation or genetic variation within components involved in this pathway contributes significantly to susceptibility for autoimmune disorders like type 1 diabetes and celiac disease. In summary, "antigen presentation via major histocompatibility complex class II molecule" describes an immunological mechanism rather than a specific druggable target protein; thus it does not fit standard conventions for therapeutic target annotation but remains central to many aspects of human health and disease biology.

Other names

MHC class II antigen presentationMajor histocompatibility complex class II-mediated antigen processingHLA class II antigen presentation (in humans)Class II MHC pathway

Drugs may affect this pathway by: - Inhibiting expression of MHC-II molecules (e.g., corticosteroids suppressing IFNγ-induced upregulation) - Modulating activity of professional antigen-presenting cells.